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ABSTRACT
Bone remodeling is the restructuring process of existing bone, which is in constant resorption and formation. Under 
normal conditions, this balanced process allows the renewal of 5 – 10% of bone volume per year.
At the microscopic level, bone remodeling is produced in basic multicellular units, where osteoclasts resorb a certain 
quantity of bone and osteoblasts form the osteoid matrix and mineralize it to fill the previously created cavity.
These units contain osteoclasts, macrophages, preosteoblasts and osteoblasts, and are controlled by a series of factors, 
both general and local, allowing normal bone function and maintaining the bone mass. When this process becomes 
unbalanced then bone pathology appears, either in excess (osteopetrosis) or deficit (osteoporosis).
The purpose of this study is to undertake a revision of current knowledge on the physiological and biological mecha-
nisms of the bone remodeling process; highlighting the role played by the regulating factors, in particular that of the 
growth factors.
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RESUMEN
El remodelado óseo es un proceso de reestructuración del hueso existente, que está en constante formación y reabsorción. 
Este fenómeno equilibrado permite, en condiciones normales, la renovación de un 5-10% del hueso total al año. A nivel 
microscópico el remodelado óseo se produce en las unidades básicas multicelulares, donde los osteoclastos reabsorben 
una cantidad determinada de hueso y los osteoblastos forman la matriz osteoide y la mineralizan para rellenar la cavidad 
previamente creada. En estas unidades hay osteoclastos, macrófagos, preosteoblastos y osteoblastos y están regidos por 
una serie de factores, tanto generales como locales, permitiendo el normal funcionamiento del hueso y el mantenimiento 
de la masa ósea. Cuando este proceso se desequilibra aparece la patología ósea, bien por exceso (osteopetrosis) o por 
defecto (osteoporosis). 
El propósito de este trabajo es realizar una revisión de los conocimientos actuales sobre los mecanismos bioquímicos 
y fisiológicos del proceso de remodelado óseo, resaltando de manera especial el papel de los factores reguladores del 
mismo, entre los que destacan los factores de crecimiento.
Palabras clave: Hueso, regeneración, remodelado, reabsorción, osteogénesis, factores de crecimiento.
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INTRODUCTION
Bone is a dynamic tissue, in constant resorption and forma-
tion, permitting the maintenance of bone tissue, the repair 
of damaged tissue and the homeostasis of the phosphocalcic 
metabolism. Through this balanced phenomena, known as 
the remodeling process, about 5% of cortical bone and 20% 
of trabecular bone is renewed per year. Although cortical 
bone makes up 75% of the total volume, the metabolic rate 
is 10 times higher in trabecular bone since the surface area 
to volume ratio is much greater (trabecular bone surface 
representing 60% of the total). Therefore, approximately 5 
to 10% of total bone is renewed per year. Bone remodeling 
occurs throughout life, but only up to the third decade is 
the balance positive. It is precisely in the third decade when 
the bone mass is at its maximum, this is maintained with 
small variations until the age of 50. From then on resorption 
predominates and the bone mass begins to decrease.
At the microscopic level, bone remodeling takes place in 
small areas of the cortical and the trabecular surface, known 
as basic multicellular units (BMU). Resorption always pre-
cedes formation and in the young skeleton the amount of 
resorbed bone is similar to the newly formed. For this reason 
it is referred to as a balanced process, linked in both space 
and time under normal conditions (1). The average lifespan 
of each remodeled unit in humans is 2 to 8 months, the 
greater part of this time being taken up by bone formation. 
There are 35 million basic multicellular units in the human 
skeleton, and 3-4 million are activated each year, thus the 
skeleton is completely renewed every 10 years.
1. REMODELING PHASES
Bone remodeling can be divided into the following phases 
(fig 1) (2): quiescent, activation, resorption, formation, 
mineralization.
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Fig. 1. Bone remodeling  phases (modified from Compston) (2). 
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1.1 Quiescent phase: said of the bone when at rest. The fac-
tors that initiate the remodeling process remain unknown.
1.2 Activation phase: the first phenomena that occurs is the 
activation of the bone surface prior to resorption, through 
the retraction of the bone lining cells (elongated mature 
osteoblasts existing on the endosteal surface) and the diges-
tion of the endosteal membrane by collagenase action. Once 
exposed, the mineralized surface attracts the circulating 
osteoclasts coming from the nearby vessels.
1.3 Resorption phase: the osteoclasts then begin to dissolve 
the mineral matrix and decompose the osteoid matrix. This 
process is completed by the macrophages and permits the 
release of the growth factors contained within the matrix, 
fundamentally transforming growth factor beta (TGF-β), 
platelet derived growth factor (PDGF), insulin-like growth 
factor I and II (IGF-I and II).
1.4 Formation phase: simultaneously in the resorbed areas 
the preosteoblast grouping phenomena is produced, at-
tracted by the growth factors liberated from the matrix 
which act as chemotactics and in addition stimulate their 
proliferation (3). The preosteoblasts synthesize a cemen-
ting substance upon which the new tissue is attached, and 
express bone morphogenic proteins (BMP) responsible for 
differentiation. A few days later, the already differentiated 
osteoblasts synthesize the osteoid material which fills the 
perforated areas.
1.5 Mineralization phase: mineralization begins thirty days 
after deposition of the osteoid, ending at 90 days in the 
trabecular and at 130 days in the cortical bone.
The quiescent or ‘at rest’ phase then begins again.
2. REGULATORY FACTORS IN BONE REMO-
DELING
The balance between bone resorption and formation is in-
fluenced by such interrelated factors as genetic, mechanical, 
vascular, nutritional, hormonal and local.
2.1 Genetic factors
These are important in determining the maximum bone 
mass, since between 60 and 80% of this is genetically de-
termined (4). Thus, Negroes have a greater bone mass than 
Whites, who in turn have a higher mass than Asians. Bone 
mass is a characteristic transmitted from parents to children, 
which is why daughters of mothers with osteoporosis are 
more predisposed to having this condition themselves (5).
2.2 Mechanical factors
Physical activity is essential for the correct development of 
bone. It is believed that muscular action transmits tension to 
the bone, which is detected by the osteocyte network within 
the osseous fluid. These osteocytes produce regulators such 
as prostaglandins, nitric oxide and IGF-I, which stimulate 
both their own and the osteoblast activity, increased bone 
formation. On the other hand, the absence of muscular ac-
tivity, rest or weightlessness has an adverse effect on bone, 
accelerating resorption (6).
2.3 Vascular/nerve factors
From studies by Trueta (7) it is known that vascularization 
is fundamental for normal bone development, supplying 
blood cells, oxygen, minerals, ions, glucose, hormones and 
growth factors. Vascularization constitutes the first phase in 
ossification: the blood vessels invade the cartilage and later 
produce resorption via the osteoclasts originating from the 
nearby vessels. In the same way, vascular neoformation is the 
first event in the repair of fractures or bone regeneration, 
since the supply of oxygen is fundamental to the production 
of the restitutio ad integrum rather than fibrous tissue. Ham 
described this phenomenon in 1952 (8), observing that the 
osteocytes die when they are at some distance from a capi-
llary vessel (the maximum distance being 0.1 mm).
Innervation is necessary for normal bone physiology. The 
bone is innervated by the autonomous nervous system and 
by sensorial nerve fibers. Autonomous fibers have been 
found in periosteum, endosteum, cortical bone and asso-
ciated with the blood vessels of the Volkmann conduit, and 
likewise neuropeptides and their receptors in bone. Exam-
ples of the importance of innervation in bone physiology are 
found in osteopenia and the bone fragility present in patients 
with neurological disorders, and also in the decreased bone 
density in de-nerved mandibles.
2.4 Nutritional factors
This factor is interesting because it can be modified. A 
minimum amount of calcium is needed for mineralization, 
which the majority of authors put at 1,200 mg per day to 
the age of 25, not less than 1g per day from 25 to 45, and 
following menopause should be at least 1,500 mg per day. 
Likewise, it is known that toxic habits such as smoking, 
caffeine, alcohol and excess salt constitute risk factors for 
osteopenia.
2.5 Hormonal factors
Normal development of the skeleton is conditioned by the 
correct functioning of the endocrine system, fundamentally 
of the growth hormone (GH) and the calciotropic hormo-
nes (parathyroid hormone, calcitonin, and metabolites of 
vitamin D). Hormones are systemic messengers that act at a 
distance from the site of production (endocrine effect), but 
also regulate the synthesis and action of local factors, which 
intervene directly in the cellular metabolism (autocrine and 
paracrine effects).
The most important hormones in bone physiology are:
2.5.1 Thyroid hormones: possess two opposing actions on 
bone. In the first place, they stimulate the synthesis of the 
osteoid matrix by the osteoblasts and its mineralization, 
favoring the synthesis of IGF-I. For this reason, in conge-
nital hypothyroidism (cretinism) short stature is produced 
by the alteration in bone formation. In the second place, 
a contrary effect is produced, stimulating resorption with 
the increase in number and function of the osteoclasts. The 
clinical manifestation of this effect is the appearance of bone 
loss in hyperthyroidism (9).
2.5.2 Parathyroid hormone (PTH): controls the homeostasis 
of calcium by direct action on the bone and the kidneys, 
and indirectly on the intestine. Produced in the parathyroid 
glands in response to hypocalcemia, stimulating bone 
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resorption it is the preeminent hypercalcemic hormone. 
However, in recent years a stimulating role in bone forma-
tion, through the synthesis of IGF-I and TGF-β, has been 
discovered (10). This dual effect of resorption and forma-
tion can be explained because the continual supply of PTH 
would stimulate bone resorption through the synthesis of 
a factor favoring osteoclastogenesis (RANKL) on the part 
of the osteoblastic cells, while at intermittent doses it would 
stimulate the formation of bone, associated with an increase 
of the above mentioned growth factors and with a decrease 
in the apoptosis of the osteoblasts.
2.5.3 Calcitonin: is produced in the C, or parafollicular, cells 
of the thyroid, it is an inhibitor of bone resorption, reducing 
the number and activity of the osteoclasts. However, this is a 
transitory action, since the osteoclasts seem to become ‘imper-
meable’ to calcitonin within a few days (11).
2.5.4 1.25(OH)2 vitamin D3 or calcitriol: a steroid hormone 
which favors the intestinal absorption of calcium and phos-
phate, and therefore bone mineralization. It is necessary 
for normal growth of the skeleton. Some authors believe it 
may be produced by lymphocytic or monocytic bone cells, 
playing an important role as a local regulator of osteoclast 
differentiation (12).
2.5.5 Androgens: have an anabolic effect on bone through 
the stimulation of the osteoblast receptors. Likewise, they 
act as mediators of the peak GH in puberty. While andro-
gen deficiency is associated with lower bone density, the 
administration of testosterone in young people before the 
closure of the epiphyses increases bone mass. In the same 
way, women with an excess of androgens present higher 
bone densities.
2.5.6 Estrogens: are essential for the closure of the growth 
plates and have been discovered to play an important role 
in the development of the skeleton, both masculine and fe-
minine, during adolescence. Estrogens have a dual effect on 
bone metabolism: on the one hand they favor bone forma-
tion, increasing the number and function of the osteoblasts, 
and on the other they reduce resorption. Estrogen receptors 
have been described in human osteoblasts, osteocytes and 
osteoclasts. Recent investigations have found that estrogens 
can increase the levels of osteoprotegerin (OPG), a protein 
produced by osteoblasts that inhibits resorption (13), so 
they may play an important role in the regulation of osteo-
clastogenesis. For this reason estrogen deficiency during 
menopause constitutes the most important pathogenic 
factor in bone loss associated with osteoporosis.
2.5.7 Progesterone: also has an anabolic effect on bone, 
either directly, through the osteoblasts which possess hor-
mone receptors, or indirectly, through competition for the 
osteoblastic receptors of the glucocorticoids.
2.5.8 Insulin: stimulates matrix synthesis both directly and 
indirectly, increasing the hepatic synthesis of IGF-I (insulin-
like growth factor).
2.5.9 Glucocorticoids: at high doses they have a catabolic 
effect on bone, since they inhibit the synthesis of IGF-I by 
the osteoblasts, and directly suppress BMP-2 and Cbfa1, 
critical factors in osteoblastogenesis (14). However, recent 
studies have demonstrated that at physiological doses they 
have an osteogenic capacity favoring osteoblastic differen-
tiation (15). 
2.5.10 Growth Hormone: acts both directly and indirectly 
on bone. Growth hormone acts directly on the osteoblasts 
with hormone receptors, stimulating their activity, thus 
increasing the synthesis of collagen, osteocalcin and alka-
line phosphate. The indirect action is produced through an 
increase in synthesis of IGF-I and II by the osteoblasts. 
These factors stimulate the proliferation and differentiation 
of the osteoblasts, increasing their number and function. 
GH has been considered as a local growth factor, since it 
is not only synthesized in the adenohypophysis, but also in 
almost all the cells of the organism, including osteoblasts 
(16), having both an autocrine and paracrine effect in addi-
tion to the endocrine.
2.6 Local factors
Bone remodeling is also regulated by local factors, among 
which principally growth factors and cytokines, and recently 
the bone matrix proteins have been implicated as modulators 
of other local factors (table 1). Bone cells also play an im-
portant role in the production of prostaglandins and nitric 
oxide, as well as cytokines and growth factors.  
2.6.1 Growth factors
These are polypeptides produced by the bone cells themsel-
ves or in extra-osseous tissue, and act as modulators of the 
cellular functions, fundamentally growth, differentiation, 
and proliferation (table 1).
IGF-I and II (insulin-like growth factor I and II): these are 
polypeptides similar to insulin; they are synthesized by the 
liver and osteoblasts, and found in high concentrations 
in the osteoid matrix (17). They increase the number and 
function of the osteoblasts, stimulating collagen synthesis. 
They circulate linked to IGF-binding proteins (IGFBP), 
which in turn can exercise stimulatory or inhibitory effects 
on bone. IGF synthesis is regulated by hormones and local 
growth factors; thus GH, estrogens and progesterone in-
crease their production, while the glucocorticoids inhibit it. 
They also mediate in the osteoblast-osteoclast interaction 
and actively participate in bone remodeling (18). IGF-II is 
the most abundant factor in the bone matrix, it is important 
during embryogenesis, but its effects on the fully developed 
skeleton are as yet unknown (19).
Transforming Growth Factor-β (TGF-β): is a superfamily of 
proteins highly abundant in bone tissue (second after IGF). 
They are latently present in the matrix and activate during 
osteoclastic resorption. TGF-β is a potent stimulator of bone 
formation, promoting osteoblastic differentiation and the 
synthesis of the osteoid matrix, and inhibiting the synthesis of 
the proteases (especially the matrix metalloproteinase (MMP), 
an enzyme which degrades it).
Likewise, TGF-β inhibits resorption on reducing the forma-
tion and differentiation of the osteoclasts, as well as mature 
osteoclast activity and stimulating their apoptosis (20).
However, in addition to these functions, it has been disco-
vered to inhibit epithelial proliferation and mediate in the 
anabolic effect of the androgens.
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Bone Morphogenetic Proteins (BMP): are included in the 
TGF-β family. They form a group of  15 proteins able 
to achieve the transformation of  connective tissue into 
bone tissue, for which they are considered osteoinductive. 
Likewise, they are able to stimulate the differentiation of the 
stem cells towards different cell lines (adipose tissue, cartila-
ge and bone). They are highly abundant in bone tissue, and 
during embryogenesis participate in the formation of bone 
and cartilage. They are currently considered to be the most 
powerful factors in osteoblastic differentiation (21). Canalis 
et al. (22) believe that besides stimulating osteogenesis, they 
inhibit osteoclastogenesis.
Platelet-Derived Growth Factor (PDGF): on the one hand it 
stimulates proteic synthesis brought about the osteoblasts 
(23), and on the other, favors bone resorption. Other effects 
are the proliferation of  fibroblasts and smooth muscle 
cells, neovascularization, and collagen synthesis, therefore 
favoring scarring.
Fibroblastic Growth Factor (FGF): has an anabolic effect on 
bone, as it is a mitogen of osteoblasts, vascular endothelial 
cells, and fibroblasts. As a practical example of the effect 
of FGF it is known that mutations in its receptors produce 
alterations in the craniofacial skeleton, such as achondro-
plasia, Apert’s syndrome and Crouzon’s syndrome, among 
others (24).
Epidermal Growth Factor (EGF): is a powerful mitogen of 
cells of mesodermic or ectodermic origin. 
It is synthesized in many tissues and could therefore be 
involved in diverse, as yet unexplained, biological func-
tions. With respect to bone, it could have a dual formative 
and destructive action, although the latter is the most well 
known.
Vascular Endothelial Growth Factor (VEGF): induces angio-
genesis and vascular endothelial proliferation. It produces 
vasodilation and an increase in vascular permeability. It is 
produced in hypoxia and is currently considered one of the 
key factors in the first phases of fracture repair and bone 
regeneration, as well as in tumor growth.
Granulocyte/Macrophage-Colony Stimulating Factor (GM-
CSF): is important in osteoclastogenesis and may play a role 
in the pathogeny of osteopetrosis.
Macrophage-Colony Stimulating Factor (M-CSF): is pro-
duced by osteoblasts and medullar stromal cells, it is an 
essential factor in the first phases of osteoclastogenesis being 
required for the formation of giant multinucleate cells, but 
has no effect on osteoclastic activity.
Tumor Necrosis Factor (TNF): in vitro stimulates resorption 
and has been related with bone loss in arthritis and perio-
dontal disease.
2.6.2 Matrix Proteins
The matrix proteins have recently been discovered to act 
as growth factor modulators (25). It should be taken into 
account that matrix proteins are found in concentrations 
a thousand times higher than growth factors, and could 
therefore play a more important role in the regulation of 
the different cell functions (26).
Furthermore, these matrix proteins also participate in regu-
lation of the differentiation of the cells contained within the 
matrix. For example, collagen I is one of the earliest mar-
kers which regulates the osteoprogenitor cells, and alkaline 
phosphatase is a surface protein that could participate in the 
regulation of the proliferation, migration and differentiation 
of the osteoblastic cells.
 Stimulate bone formation Stimulate bone resorption Inhibit bone resorption 
       Growth 
Factors 
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                IFN-� 
IL-4 
Table 1. Regulatory local factors in bone remodeling.
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 FORMATION RESORPTION 
PLASMA 
 
OCN: specific from bone and dentin 
(mineralized tissues). It is synthesized by 
osteoblasts and  released into circulation 
in low levels.  OCN synthesis is 
dependent on vitamin K and D. OCN is 
increased when bone turnover is 
increased. 
PICP: low sensitivity. It is released into 
circulation in a ratio 1/1. 
 ALP: low sensitivity  but high specificity 
in osteoporosis.  
Calcium/Creatinine 
 
TRAP: low specificity 
ICTP 
URINE 
       
     Calcium 
Hydroxyproline: low sensitivity (hydroxyproline 
also proceed  
from food). It is a good marker when bone 
resorption is exaggerated,  
for example in Paget disease. 
Hydroxylysine: better marker than previous. 
Pyridinolines (Pyr): The most promising 
resorption marker. In human bone the ratio 
pyridinolines/ deoxypyridinolines is 3/1.  D-Pyr is 
more bone specific. They are excreted by urine 
(40% in a free form  
and 60% linked to plasmatic proteins). They are 
the most sensitivity markers and  provide a highly 
specific marker of bone resorption (interesting in 
osteoporosis). 
INTP 
Table 2. Markers of bone metabolism.
OCN: Osteocalcin
PICP: Procollagen I carboxyterminal Propeptide 
ALP:  Alkaline phosphatase 
TRAP: Tartrate resistant acid phosphatase 
ICPT:  Procollagen I C-terminal Telopeptide 
INTP: Procollagen I N-terminal Telopeptide 
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2.6.3 Cytokines
These are polypeptides synthesized in the lymphocytic and 
monocytic cells and play an important role in multiple 
cellular functions, such as the immunological response, 
inflammation and hematopoiesis, having both an autocrine 
and paracrine effect.
The following are important in bone:
- Interleukin 1 (IL-1): directly stimulates osteoclastic re-
sorption, increasing the proliferation and differentiation of 
the pre-osteoblasts as well as the osteoclastic activity and 
inhibiting the apoptosis of the osteoclasts (2). In reality, 
they are 3 different related molecules: IL-1α, IL-1β and the 
IL-1 receptor antagonist, this last being the inhibitor of the 
first two. Its action on resorption, through the synthesis of 
prostaglandins, is both direct and indirect.
 - Interleukin 6 (IL-6): stimulates bone resorption and ap-
pears to be implicated in the pathogenesis of Paget’s disease 
(27). It is believed to play an important role in the initial 
stages of osteoclastogenesis, and is produced in response to 
PTH, IL-1 and 1.25(OH)2D3.
- Interleukin 11 (IL-11): recently discovered, it is produced 
in bone marrow and induces osteoclastogenesis.
- Prostaglandins (PG): in vitro stimulate bone resorption, 
fundamentally PGE2, but also PGE1, PGG2, PGI2 and PGH2 
(28). Studies in vivo, measuring the prostaglandin levels in 
the crevicular liquid, have demonstrated its participation 
in the bone destruction that takes place in periodontal 
disease (29).
3. BIOCHEMICAL MARKERS OF BONE META-
BOLISM
The biochemical markers of bone metabolism are interesting 
from the clinical point of view in evaluating the remodeling 
process. Thus, there are markers of bone formation, such 
as alkaline phosphatase, osteocalcin and procollagen type 
I (PICP); and markers of resorption, such as hydroxypro-
linuria and tartrate resistant phosphatase acid. Of the 11 
most frequently used biochemical markers to measure bone 
resorption and formation, 9 are extracellular matrix proteins 
(25). The markers of osteo-formation are products of the 
osteoblasts at their different stages of differentiation (30) 
(table 2).
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